Downregulation of the cellular retinol-binding protein-I (CRBP-I) occurs in breast and other human cancers, but its significance is not well understood. Recently, we showed that restoration of CRBP-I expression in transformed MTSV1-7 breast epithelial cells increased retinoic receptor activity, inhibited anoikis, promoted acinar differentiation and inhibited tumorigenicity, suggesting that CRBP-I suppresses tumor progression. However, the mechanism underlying these effects of CRBP-I was not elucidated. Here we demonstrate, using genetic and pharmacological approaches, that CRBP-I inhibits, in a retinoic acid receptor-dependent manner, the PI3K/Akt survival pathway. Inhibition of PI3K/Akt was necessary and sufficient to explain the antitumor effects of CRBP-I and was mediated by decreased p85 regulatory and p110 catalytic subunit heterodimerization. We present evidence consistent with the idea that this effect is due to CRBP-I inhibition of p85 phosphorylation at Y688. To our knowledge, this is the first demonstration of PI3K regulation at the level of p85-p110 heterodimerization. These findings lead us to hypothesize that CRBP-I downregulation in cancer promotes tumor progression through inhibition of retinoic acid receptor activity and derepression of PI3K/Akt signaling via a novel mechanism.
Introduction
The biologic effects of vitamin A (other than vision) are primarily mediated by receptors for the acid form of the vitamin, that is, retinoic acid (RA). Two conserved families of nuclear receptors belonging to the superfamily of ligand-dependent transcription factors encode RA receptors: RARs, which bind both all-trans RA, the natural isoform, and its 9-cis RA isomer, and RXRs, which bind only 9-cis RA. RARs and RXRs function cooperatively through heterodimerization, actively repressing and activating target gene transcription in the absence and presence of ligand, respectively (reviewed in Mangelsdorf, 1994; Torchia et al., 1998) . Although the receptors bind RA, the blood delivers vitamin A to tissues mainly in its alcohol form (retinol), such that cells must be able to take up retinol and oxidize it to RA in order to activate RXR-RAR (Kurlandsky et al., 1995) .
Cellular retinol-binding protein-I (CRBP-I) is a widely expressed, highly evolutionarily conserved protein that is conceptualized as a chaperone that presents retinol to its metabolizing enzymes (Napoli, 1999) . The study of mice in which CRBP-I was homozygously inactivated demonstrated an essential role for CRBP-I in central (liver) vitamin A esterification and storage (Ghyselinck et al., 1999) . Other studies have shown that CRBP-I exerts a similar enhancement of vitamin A storage in peripheral cells, including breast epithelial cells (Nilsson et al., 1997; Kuppumbatti et al., 2001; Dirami et al., 2004) , but the significance of local vitamin A storage in target tissues was not understood. However, the finding that CRBP-I is epigenetically silenced in breast cancer Esteller et al., 2002) suggested that CRBP-I plays a functional role in the breast epithelium. In support of this hypothesis, we showed earlier that restoration of CRBP-I expression in a transformed breast cell line inhibits anchorage-independent growth (AIG) by promoting the apoptotic death of anchorage-deprived cells (Kuppumbatti et al., 2001 ), a process termed anoikis (Frisch and Francis, 1994) . More recently, we demonstrated that CRBP-I induces acinar differentiation in reconstituted basement membrane and, to a lesser extent, in collagen I (Farias et al., 2005 , and data not shown). Acinar differentiation also entails the anoikis of intraluminal cells, that is, those deprived of contact with extracellular matrix proteins (Debnath et al., 2002) . Both of these effects (promotion of anoikis and induction of differentiation) inhibit tumor growth. Importantly, we found that they are mediated through the downstream activation of RARs (Farias et al., 2005) , thus linking CRBP-I-driven local retinyl ester storage to local RAR activation. This key finding places the observation that CRBP-I is downregulated in breast cancer in perspective, that is, it suggests that, under physiological conditions (retinol as main retinoid source), CRBP-I silencing is tantamount to inhibition of RAR function even when RARs are normally expressed (Seewaldt et al., 1995; Kuppumbatti et al., 2000) .
Phosphatidylinositol 3-kinase (PI3K) is a critical signaling node that is regulated in response to the activation of growth factor receptors, G protein-coupled receptors, integrins and other cell signals that impact on cell survival and apoptosis. Class Ia PI3Ks consist of a regulatory (most commonly p85) and a catalytic (p110) subunit and catalyze the phosphorylation of phosphatidylinositol at the 3-hydroxy position of the inositide ring. The formation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) from phosphatidylinositol 4,5-bisphosphate is of particular relevance because PIP3 recruits downstream effectors to the plasma membrane (Cantley, 2002) . One such effector is Akt, which is activated by phosphoinositide-dependent kinase 1 which is likewise recruited to PIP3 sites. Akt is a serinethreonine protein kinase that once activated acts to inhibit apoptosis by phosphorylation of several key substrates (Brazil et al., 2004) .
In the present report, we investigated the mechanism whereby CRBP-I induces breast epithelial cell anoikis and acinar differentiation. We show that CRBP-I acts as a potent inhibitor of the PI3K/Akt survival pathway through the intermediation of RAR activation and that this effect of CRBP-I is sufficient to explain its antitumor effects. Further, we associate CRBP-I with regulation of p85-p110 heterodimer formation. These findings highlight a novel mechanism of PI3K regulation and define a new interface between vitamin A metabolism and RAR activation on one hand, and PI3K/Akt suppression on the other.
Results

CRBP inhibits Akt activity
We have shown that ectopic CRBP-I inhibits AIG and induces acinar differentiation in MTSV1-7 cells (see Introduction). We hypothesized that these effects were mediated by inhibition of a survival pathway that allows cells to overcome anoikis. Our earlier finding that CRBP-I inhibited Akt activity in cells deprived of anchorage supported this hypothesis (Kuppumbatti et al., 2001) . To extend this finding, we measured Akt activity in MTSV1-7 cells under conditions that inhibit anoikis (adherent monolayers) or render cells susceptible to it (collagen I gels or suspension cultures). This showed that CRBP-I markedly inhibits Akt activity in cells in collagen I or in suspension relative to adherent monolayers (Figure 1a ), suggesting that Akt inhibition is a critical path through which CRBP-I promotes anoikis.
In addition to the restoration-of-function approach described above, we also analyzed the effect of CRBP-I on Akt activity using a loss-of-function approach. Mammary epithelial cells (MEC) were isolated from wild-type and CRBP-I null female mice and immortalized by introduction of the SV40 large T (LT) antigen (the resulting cell lines are referred to as MECSV WT and MECSV KO , respectively). We found that Akt activity in MECSV WT in collagen I or in suspension, but not on plastic, was clearly lower than in MECSV KO , providing independent evidence that CRBP-I inhibits Akt activity under anoikis-inducing conditions (Figure 1b) .
Unless otherwise specified, the experiments that follow were performed using cells in suspension, an assay that was quick and reliable.
CRBP-I inhibition of Akt activity is RAR-dependent
We have shown that the differentiation-inducing effect of CRBP-I was mediated by RAR activation, leading us to expect that CRBP-I inhibition of Akt activity is also ) cells with the RAR antagonist Ro 41-5253 (Apfel et al., 1992) raised the P-Akt/Akt ratio (Figure 1d ). These findings strongly suggest that RAR activation mediates the CRBP-I inhibition of Akt activity.
CRBP-I inhibits PI3K and this effect explains the CRBP-I induction of cell differentiation
Akt phosphorylation reflects PI3K activation. Nevertheless, to test directly whether CRBP-I inhibited PI3K activity, we compared the ability of p85 immunoprecipitates to phosphorylate phosphatidylinositol at the 3-hydroxy position. PI3K activity was lower in MTSV CRBP-I relative to MTSV vector cells grown in collagen I, and this difference correlated with the difference in Akt activity as determined in the same cell lysates, thus confirming that CRBP-I regulates PI3K itself ( Figure 2A ). We have shown that LY294002, a specific PI3K inhibitor at low concentrations, mimicked the CRBP-I inhibition of MTSV1-7 AIG (Kuppumbatti et al., 2001) . We now tested whether LY294002 also mimicked the CRBP-I induction of MTSV1-7 differentiation in 3D reconstituted basement membrane (RBM). As expected (Farias et al., 2005) , untreated MTSV vector cells formed undifferentiated, disorganized outgrowths, a representative example of which is shown in Figure 2B (panel a). In contrast, in the presence of 10 mM LY294002, MTSV vector cells formed differentiated acini (panel b). Similar results were obtained using wortmannin, another PI3K inhibitor. In addition, LY294002 and wortmannin also restored the ability of MECSV KO to differentiate (not shown). Notably, inhibitors of other pathways, such as PD98059 (Erk inhibitor), rapamycin (mTOR inhibitor), and PP2 (src inhibitor) did not affect cell differentiation to the same extent although partial effects were seen.
Conversely, we tested whether transient expression of constitutively active p110 could block MTSV CRBP-I differentiation in RBM. Untreated MTSV CRBP-I cells, as expected, exhibited acinar differentiation ( Figure 2B , panel c) and this phenotype was inhibited by constitutively active p110 (panel d). Taken together, these findings argue that PI3K inhibition is necessary and sufficient for the differentiation induction effect of CRBP-I.
CRBP-I inhibits PI3K activity by regulating p85-p110 subunit association
We hypothesized that CRBP-I regulated PI3K by altering the overall abundance of p85 or p110 subunits. However, this hypothesis was not supported by immunoblot analysis of total p85 and p110 levels in CRBP-I expressing (MTSV CRBP-I or MECSV WT ) versus nonexpressing cells (MTSV vector or MECSV KO ), Figure 3a .
The catalytic activity of p110 is suppressed by p85 Cterminal motifs (Chan et al., 2002; Jimenez et al., 2002) , an effect that is relieved by interaction of phosphotyrosine residues on growth factor receptor or adaptor proteins with the SH2 domains of p85 and/or by p85 phosphorylation (Cuevas et al., 2001; Cantley, 2002; Chan et al., 2002; Jimenez et al., 2002) . The fact that the p85-p110 heterodimer can be switched from an 'off' to an 'on' state implies that PI3K activity is ultimately proportional to p85-p110 heterodimer abundance. We therefore tested the alternative hypothesis that CRBP-I regulated the extent of p85-p110 heterodimer formation. This hypothesis was tested by p110 immunoprecipitation followed by p85 immunoblotting; the immunoprecipitate was also immunoblotted for p110 to control for differences in immunoprecipitation efficiency. As shown in Figure 3b , CRBP-I-expressing cells (MTSV CRBP-I or MECSV WT ) had markedly lower levels of p85 associated with p110 relative to CRBP-I nonexpressing cells (MTSV vector or MECSV KO ), thus supporting our alternative hypothesis ( Figure 3b ).
As before, we sought to determine whether the effects of CRBP-I, in this case its inhibition of p85-p110 heterodimerization, could be mimicked by RA treatment of MTSV vector cells. This was tested using pooled and clonal MTSV vector cell lines. In either cell preparation, RA treatment for 10 days mimicked the effect of ectopic CRBP-I, decreasing p85-p110 abundance (Figure 3c ), again linking the effects of CRBP-I to RAR activation.
Our hypothesis that decreased p85-p110 heterodimerization accounts for the CRBP-I inhibition of PI3K/Akt activity is seemingly contradictory with the constitutive activity of free p110 (Cantley, 2002) . Thus, decreased subunit association in presence of CRBP-I predicts that free p110 levels and thus PI3K activity should be increased. Nevertheless, the consistent inhibitory effect of CRBP-I on Akt activity suggests that PI3K activity is decreased rather than increased when fewer p85-p110 heterodimers are formed, suggesting that free p110 may not be active. To test directly whether free p110 was active in our model system, we repeated the PI3K assay but this time immunoprecipitated with anti-p110 antibody to bring down both heterodimerized and free p110. As shown in Figure 4 , PI3K activity was inhibited by CRBP-I under these conditions, mirroring the results in Figure 2A . Moreover, PI3K activity was once again associated with p85-p110 heterodimer levels. This and p110 immunoblots (IB) from total lysates prepared from cells cultured in suspension for 1 h. Total Akt was used as loading control. (b) p85-p110 heterodimer levels in total lysates from cells cultured in suspension for 1 h. Cell lysates were immunoprecipitated with anti-p110 and the IP material blotted and probed for p85 (indicates level of subunit association) and p110 (controls for the efficiency of immunoprecipitation). In the p85 IB of this experiment, a slower migrating, nonspecific band can be seen; because it was poorly resolved from p85, this band was included in the quantitation of the data. (c) p85-p110 heterodimer levels in total lysates (same protocol as in (b)) were assayed in two different preparations of MTSV vector cells treated with vehicle alone or 1 mM all-trans RA for 10 days then cultured in suspension for 1 h Figure 4 CRBP-I inhibits the PI3K activity of p110 immunoprecipitates. Cells cultured in suspension for 1 h were immunoprecipitated with anti-p110 antibody (IP p110) then assayed for PI3K activity (PI3P) and p85 abundance in the IP material (IB p85). As controls, the IP material was probed for p110 (IB p110) and total lysates for p85
suggests that free p110 is not active in our model system, although the reason why this might be remains unclear.
CRBP-I regulates p85-p110 dimerization through a novel mechanism
Little is known about the mechanisms that regulate p85-p110 heterodimer formation. Mechanisms that alleviate the repressive effect of p85 on p110 activity usually act on preformed p85-p110 heterodimer. However, in theory, such mechanisms might instead promote the productive association of p85 with p110, that is, de novo formation of an active complex. This theoretical scenario was raised in another report concerning the mechanism whereby Y688 phosphorylation relieves the inhibitory effect of C-terminal p85 motifs on small GTPase activation of p110 (Chan et al., 2002) . We therefore asked whether p85-p110 association in starved cells (serum and insulin deprived) differed from cells that were first starved then released from starvation (serum and insulin added). As serum and insulin activate PI3K, any such difference would imply a correlation between PI3K activation and subunit association. We found that p85-p110 association was decreased in continuously starved cells as compared to cells released from starvation (Figure 5a , top half, compare lanes 1 and 3, and 2 and 4). Notably, subunit association was decreased in MTSV CRBP-I relative to MTSV vector cells under either experimental condition (compare lanes 1 and 2, and 3 and 4). These results demonstrate that PI3K activation by serum and insulin is correlated with subunit association and that both events are diminished by CRBP-I.
Role of p85 phosphorylation
We next tested whether these data correlated with the recruitment of p85 to tyrosine-phosphorylated proteins or p85 phosphorylation (i.e., p85 activation). We immunoprecipitated cell lysates with anti-P-Tyr antibodies and immunoblotted for p85. The p85 immunoblot signal for continuously starved cells was decreased relative to cells released from starvation (Figure 5a , bottom half, compare lanes 1 and 3, and 2 and 4), supporting the idea that p85 activation correlates with PI3K subunit association (Figure 5a , compare top and bottom halves). Again, MTSV CRBP-I cells displayed a lower signal relative to MTSV vector cells (compare lanes 1 and 2, and 3 and 4) under either experimental condition, strengthening our hypothesis that p85 activation and p85-p110 dimer formation are associated events.
As a result of the important role of p85 phosphorylation in its activation, we hypothesized that p85 phosphorylation, specifically on Y688 (Cuevas et al., 2001) , is inhibited by CRBP-I leading to decreased formation of productive PI3K heterodimers. Since Y688 phospho-specific antibodies were not available, we tested this hypothesis by transiently cotransfecting CD20 (surface marker for cell sorting) and p85 Y688D (phosphomimetic mutant) into MTSV CRBP-I cells and asking whether this reversed the effects of CRBP-I, i.e., whether it (a) increased Akt activity; (b) increased the degree of p85-p110 dimerization and (c) decreased anoikis. The extent of p85 Y688D overexpression is illustrated in Figure 5b (top panel). Remarkably, p85 Y688D elicited each of these effects, although the increase in subunit association was more modest than the increase in Akt activity (Figure 5b-d) . These results lead to the novel mechanistic hypothesis that p85 phosphorylation on Y688 activates PI3K by promoting p85 and p110 association. An extension of this hypothesis is that CRBP-I's antitumor effects derive from its ability to antagonize this mechanism.
CRBP-I inhibits Akt and induces differentiation in T47D breast cancer cells
To extend some of our key findings to a different breast cancer model, we tested the effect of CRBP-I on Akt activity and cell differentiation in T47D cells, which are . Ectopic CRBP-I expression under the Tet-off regulator yielded T47D cells that expressed low (promoter leakiness in presence of tetracycline) and high CRBP-I protein levels (absence of tetracycline, Figure 6a , top panel). CRBP-I dose-dependently decreased p85-p100 heterodimer formation (Figure 6a second and third panel), inhibited Akt activity (Figure 6a , lower panels) and promoted cell differentiation in RBM (Figure 6b ; compare also left panels in Figures 6c and d) . As predicted by the MTSV1-7 model, RAR antagonist treatment blocked CRBP-I-induced differentiation (Figure 6c ), and treatment with LY294002 mimicked the effect of CRBP-I (Figure 6d ). These results suggest that a similar chain of events (RAR activation, decreased p85-p110 dimerization and PI3K/Akt inhibition) underlie the CRBP-I inhibition of cell survival and induction of differentiation in the SV40-based MTSV1-7 and the T47D models.
Discussion
Our data argue that CRBP-I and RAR-dependent inhibition of PI3K signaling in MTSV1-7 cells (Figures  1 and 2 ) underlies the antitumor effects of CRBP-I we have described (Kuppumbatti et al., 2001; and Farias et al., 2005) . The MTSV1-7 model is fitting in this context since MTSV1-7 transformation is driven by the SV40 LT and small t (st) antigens and PI3K activation is a key transforming effect of st (Zhao et al., 2003) . In the two other models we have used (LT-immortalized mouse MECSV and T47D human breast cancer cells), the role of PI3K in driving transformation is less well established but is consistent with several literature reports (Neve et al., 2002; Singh et al., 2002; Yu and Alwine, 2002; Acosta et al., 2003) . Further work is needed to more precisely define the molecular context in which CRBP-I loss may contribute to disease progression. However, CRBP-I inhibition of PI3K/ Akt, demonstrated here in three different genetic backgrounds, is likely to remain a central feature, particularly in view of recent work demonstrating that PI3K/ Akt inhibition restores and PI3K/Akt activation disrupts acinar differentiation in other breast cancer models (Wang et al., 2002; Debnath et al., 2003; Liu et al., 2004) .
Our finding that CRBP-I regulation of PI3K is strictly dependent on a 3D context (Figure 1 ) is reminiscent of work demonstrating 3D regulation of signaling pathways that control cell growth and differentiation (Wang et al., 1998; Muthuswamy et al., 2001) . As a result of the importance of integrins in regulating 3D cell differentiation and survival (Frisch and Francis, 1994; Weaver et al., 1997) an area for future development is the interaction between RAR and integrin signaling.
As pointed out earlier, the fact that PI3K heterodimers can be switched from an 'off' to an 'on' state implies that PI3K/Akt activity is ultimately proportional to p85-p110 heterodimer abundance. Our finding that CRBP-I/RAR inhibits heterodimer levels (Figure 3 ) supports the idea that it is this effect that accounts for the CRBP-I inhibition of PI3K/Akt activity. Although, not surprisingly, P-Akt/Akt and p85/p110 ratios for a given cell preparation varied from experiment to experiment, consideration of the overall relative effect of CRBP-I on these parameters (experimental range of 5-20-fold and 2.5-13-fold inhibition, respectively) is consistent with the above notion.
Our hypothesis that CRBP-I inhibition of p85-p110 heterodimerization and Akt activity are linked is challenged by the expectation that decreased subunit association would lead to increased free p110 levels and thus increased PI3K activity. However, for reasons that remain unknown, free p110 is not associated with increased PI3K/Akt activity in our model system (Figure 4 ). Our hypothesis is also challenged by the finding that p85 and p110 levels were the same in CRBP-I-expressing versus nonexpressing cells (Figure 3) , leading to the expectation that heterodimer abundance should be similar in the two groups, which was not the case. How then can we explain our results? (vector) and test T47D cells maintained in 2 mM tetracycline ( þ Tet) or in medium from which Tet was removed for 7 days (ÀTet). Middle and lower panels: p85-p110 heterodimer levels in total lysates from cells maintained in suspension for 1 h were determined as in Figure 3b We suggest that there is an alternative pathway of PI3K activation in which recruitment of p85 to P-Tyr residues and Src family kinase phosphorylation of p85 promotes de novo heterodimer formation rather than activate preformed heterodimers. We propose that growth factor receptor activation leads to the association of p85 in a permissive conformation with p110, such that the heterodimer formed is active. This model can explain our finding that heterodimer formation is decreased in CRBP-I-expressing cells despite no changes in p85 or p110 abundance relative to control cells. Thus, if CRBP-I inhibits the recruitment of p85 to P-Tyr residues or inhibits p85 phosphorylation, less permissive p85 would be available and less heterodimer would form. As shown in Figure 5a , P-Tyr immunoprecipitation brings down less p85 in CRBP-I-expressing cells, indicating that CRBP-I does inhibit p85 activation. The fundamental difference between our alternative and the established models of PI3K activation is the order of events: heterodimerization first followed by activation versus activation first followed by heterodimerization. Our data does not refute the prevailing model but reveals a new level of complexity. The cell models and the less common experimental design used here (immunoprecipitation of endogenous p110 followed by immunoblotting of endogenous p85) may have contributed to the uncovering of a new mechanism of PI3K regulation. Note that our data suggest that much of p110 is not associated with p85 and therefore must be stabilized by another mechanism that remains to be explored.
We recognize that most of our experiments examined subunit association under steady-state conditions and that kinetic assays will be required to address our hypothesis fully. However, the data in Figure 5a begin to address this issue. In this experiment, 20 min of serum and insulin stimulation of prestarved cells leads to growth factor activation of PI3K and an increase in p85 phosphorylation that is accompanied by a commensurate increase in p85-p110 subunit association. These data are more consistent with our hypothesis than the prevailing model, which would have predicted no increase in heterodimer abundance upon serum stimulation.
The recent demonstration that RA treatment of MCF-7 breast cancer cells decreases the amount of p85 associated with the insulin receptor substrate-1 (del Rincon et al., 2003) supports our finding that CRBP-I regulates PI3K via RAR activation but does not shed light on the PI3K activation mechanism.
Although our data does not prove that CRBP-I inhibits p85 phosphorylation on Y688, the finding that overexpression of p85 Y688D reverses the inhibitory effects of CRBP-I on PI3K subunit association, Akt activity, and anoikis ( Figure 5 ) suggest that is the case. If so, further work is needed to investigate the potential link between RAR activation and either the activity of Src family kinases that phosphorylate Y688 or the SHP-1 phosphatase that dephosphorylates it (Cuevas et al., 2001) . The role of growth factor receptors that signal at least in part via Src and regulate PI3K should also be considered given evidence that RAR agonists can inhibit growth factor receptor expression and/or signaling (Biscardi et al., 2000; Lango et al., 2003; Woods Ignatoski et al., 2003) . Finally, the role of integrin signaling also remains to be integrated.
In sum, our findings link CRBP-I/RAR to the inhibition, through an alternative mechanism, of a critical cell survival pathway strongly implicated in human cancer (Cantley and Neel, 1999) .
Materials and methods
Cells
MTSV1-7 cells (Bartek et al., 1991) and stably transfected pools (MTSV vector and MTSV CRBP-I
) have been described (Kuppumbatti et al., 2001) . The generation of MECSV KO and MECSV WT has also been described (Farias et al., 2005) . Isogenic MTSV vector and MTSV CRBP-I cells (Farias et al., 2005) were initially used to confirm results obtained with stably transfected pools (e.g., Figure 3c ) and preferentially used in subsequent experiments. Isogenic cells have the advantage that positional variegation can be confidently excluded and results assigned to differences in CRBP-I expression. MTSV1-7 cells (Kuppumbatti et al., 2001 ) and MEC were cultured as reported (Farias et al., 2005) . T47D cells were obtained from the American Type Culture Collection and grown as recommended. T47D cells expressing CRBP-I under the Tet-off regulator (kit from Clontech Laboratories, Palo Alto, CA, USA) were generated following the manufacturer's instructions.
Cells were cultured under three protocols: (a) adherent monolayers; (b) in collagen I gels (see PI3K/Akt assay below); (c) in RBM gels (see Differentiation assay below) and (d) in suspension. The latter was the most commonly used protocol: cells were starved for 16-24 h by withdrawal of serum and insulin, detached with EDTA and maintained in suspension in basal DMEM for 1 h at 371C with gentle stirring every 10 min prior to lysis and assays.
Antibodies
Antibodies to Akt, P-Akt (Ser472/473/474), CD20 and P-Tyr were purchased from BD Pharmingen, CA, USA; antibody to p85 was purchased from Upstate, VA, USA; and to p110 from Santa Cruz, CA, USA. Anti-CRBP-I peptide antibody has been described (Kuppumbatti et al., 2001) .
Cell transfection
In the experiment of Figure 2B , cells were cotransfected with constitutively active p110 (BD110) and EGFP expression vectors at a 10 : 1 ratio and after 48 h EGFP-positive cells sorted by FACS and plated in RBM. In Figure 5b -d, p85 Y688D and CD20 surface selection marker were cotransfected at a 10 : 1 ratio and after 48-72 h CD20-positive cells were selected with anti-CD20 antibody and immunomagnetic beads (Dynabeads M-450 conjugated to goat anti-mouse IgG, obtained from Dynal Biotech, ASA, Oslo, Norway) following the manufacturer's protocol. Controls consisted of cells transfected with CD20 only. Transfections were carried out using FuGene (Roche Diagnostics, IN, USA).
Immunoprecipitation
Cells were lysed for 30 min on ice with ice-cold PI3K lysis buffer plus proteinase and phosphatase inhibitors (Nguyen et al., 2000) . Lysates were centrifuged at 14 000 r.p.m. for 15 min and supernatants precleared for 1 h at 41C with protein A or G agarose beads (Roche Diagnostics, IN, USA). 500-1000 mg of precleared cell lysate protein were incubated with antibody (1 mg anti-p85, anti-p110 or antiP-Tyr antibody per 100 mg protein) at 41C for 2 h or overnight depending on the antibody. Immunocomplexes were incubated with Protein A or G agarose for 1 h at 41C, pulled down at 2500 Â g for 1 min, and washed 4 times with ice-cold PBS plus proteinase and phosphatase inhibitors. The samples were boiled for 5 min in sample buffer, centrifuged briefly, and the supernatant subjected to SDS-PAGE and standard immunoblotting as described (Farias et al., 2005) .
PI3K/Akt/p85-p110 assays
For the Akt assay shown in Figure 1a and b (center panels) and for the PI3K assay shown in Figure 2A , 2-4 Â 10 6 cells were plated in six-well plates in 2 ml collagen I (BD Bioscience, CA, USA) in growth medium and cultured for 48 h. The cultures were then washed 5 times with DMEM with 30 min incubation steps between washes to remove the growth medium, and incubated for 24 h in DMEM. Afterwards, the gels were washed twice with ice-cold PBS plus phosphatase inhibitors, mechanically fragmented, and cells plus collagen centrifuged at 1500 g for 15 min at 41C. Pellets were resuspended in 1 ml RIPA lysis buffer and homogenized in a Potter-Elvehjem homogenizer at high speed on ice and centrifuged at 14 000 g for 15 min at 41C. PI3K activity was assayed in the supernatant as described (Nguyen et al., 2000) .
Differentiation assay
In all, 5-15 Â 10 3 cells in 500 ml growth medium (2-5% FBS) supplemented with RBM (Matrigel TM , BD Biosciences, CA, USA) at 1 : 1 ratio were plated in four-well plates precoated with a thin layer of Matrigel TM and overlaid with 250 ml growth medium. The medium was replaced every 2-3 days except during drug treatments, when it was replaced daily (fresh drug added). The morphology of outgrowths formed after 1-3 weeks was monitored by inverted phase contrast microscopy at low ( Â 4 objective) and intermediate power ( Â 10 Â and Â 20 Â objective). Results shown are representative of the majority of the colonies, typically 70-90%. In Figure 6 , outgrowth morphology was monitored by hematoxylin and eosin staining of paraffin sections.
Anoikis assay
Cells were plated in poly-HEMA-coated dishes (Sigma, MO, USA) to prevent cell attachment and after 24, 48 and 96 h the percentage of viable cells was determined by Trypan blue exclusion.
